Rodolfo Perez Lopez, MD
Endocrinology · Hialeah, FLNPI 1154359479
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,043 of the $2,593 with a category attached, or 78.8%. 16 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 43.0% of the total. Reporting peaked in 2019 at $893 and has fallen 63.2% since, to $329 in 2025.
Across 94 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$1K
- Novo Nordisk$455
- Dexcom, Inc.$194
- Insulet Corporation$184
- Xeris Pharmaceuticals, Inc.$166
- Lilly USA, LLC$128
- plus $352 from 10 others
Across 1,917 payments — averaging $5738.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6.9M
- Partner Therapeutics, Inc.$2.5M
- Novo Nordisk AS$727K
- AstraZeneca$253K
- Amgen$213K
- Gilead$169K
- plus $205K from 5 others
What the payments were for
- Speaking & faculty fees$55021%
- Food & beverage$2,04379%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 26 | $1,114 |
| Novo Nordisk | 17 | $455 |
| Dexcom, Inc. | 9 | $194 |
| Insulet Corporation | 10 | $184 |
| Xeris Pharmaceuticals, Inc. | 8 | $166 |
| Lilly USA, LLC | 7 | $128 |
| Amneal Pharmaceuticals LLC | 5 | $97 |
| Corcept Therapeutics | 2 | $54 |
| Johnson & Johnson | 2 | $46 |
| AbbVie | 2 | $34 |
| Boehringer Ingelheim | 1 | $33 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Merck | 1 | $18 |
| Valeritas, Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$550
How this compares
Too few endocrinology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $115,465 |
| RybelsusSemaglutide | 69 | $67,579 |
| SynthroidLevothyroxine Sodium | 558 | $53,558 |
| MounjaroTirzepatide | 39 | $41,439 |
| JardianceEmpagliflozin | 40 | $34,238 |
| JanuviaSitagliptin Phosphate | 37 | $32,152 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $21,395 |
| TradjentaLinagliptin | 33 | $20,663 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $17,759 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $17,396 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $14,923 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 17 | $12,680 |
| Humalog Kwikpen U-100Insulin Lispro | 61 | $11,725 |
| Cinacalcet Hcl | 17 | $9,852 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 24 | $9,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $455 | $183,043180 claims |
| Boehringer IngelheimJardiance, Tradjenta | $33 | $54,90173 claims |
| AbbVieSynthroid | $34 | $53,558558 claims |
| Lilly USA, LLCMounjaro | $128 | $41,43939 claims |
| MerckJanuvia | $18 | $32,15237 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,114 | $17,04332 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $97 | $2,142246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Hialeah
- Vivian RoseCoral Springs$14K
- Bryan VinikBoca Raton$13K
- Renee FreedmanBoca Raton$10K
- Rolando RodriguezBoca Raton$8K
- Carlos ZapataTallahassee$5K
- Michael FiliMiami$4K
- Mohammad BaigTampa$2K
- Myat MyintHudson$182
- Kathryn JonesBoca Raton$142
- Alan BalsamDeerfield Beach$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.